NO20075087L - Kombinasjoner, metoder og sammensetninger for behandling av cancer - Google Patents

Kombinasjoner, metoder og sammensetninger for behandling av cancer

Info

Publication number
NO20075087L
NO20075087L NO20075087A NO20075087A NO20075087L NO 20075087 L NO20075087 L NO 20075087L NO 20075087 A NO20075087 A NO 20075087A NO 20075087 A NO20075087 A NO 20075087A NO 20075087 L NO20075087 L NO 20075087L
Authority
NO
Norway
Prior art keywords
treatment
methods
cancer
compositions
combinations
Prior art date
Application number
NO20075087A
Other languages
English (en)
Norwegian (no)
Inventor
Francis Y F Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20075087L publication Critical patent/NO20075087L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20075087A 2005-04-13 2007-10-09 Kombinasjoner, metoder og sammensetninger for behandling av cancer NO20075087L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
NO20075087L true NO20075087L (no) 2008-01-09

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075087A NO20075087L (no) 2005-04-13 2007-10-09 Kombinasjoner, metoder og sammensetninger for behandling av cancer

Country Status (12)

Country Link
US (2) US20060235006A1 (OSRAM)
EP (1) EP1868435A4 (OSRAM)
JP (1) JP2008536853A (OSRAM)
KR (1) KR20080004495A (OSRAM)
AU (1) AU2006236812A1 (OSRAM)
BR (1) BRPI0608176A2 (OSRAM)
CA (1) CA2604581A1 (OSRAM)
EA (1) EA200702238A1 (OSRAM)
MX (1) MX2007012537A (OSRAM)
NO (1) NO20075087L (OSRAM)
TW (1) TW200722091A (OSRAM)
WO (1) WO2006113304A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
DE602006021312D1 (de) * 2005-06-09 2011-05-26 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
AU2007234382B2 (en) * 2006-04-05 2011-06-09 Novartis Ag Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
MX2008012903A (es) * 2006-04-07 2008-10-13 Novartis Ag Uso de inhibidores de c-src en combinacion con un compuesto de pirimidilaminobenzamida para el tratamiento de la leucemia.
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
CA2730715C (en) * 2008-08-04 2013-10-01 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010077894A2 (en) * 2008-12-16 2010-07-08 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
AU2010302961A1 (en) * 2009-10-01 2012-04-19 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
CA2604581A1 (en) 2006-10-26
EA200702238A1 (ru) 2008-04-28
WO2006113304A2 (en) 2006-10-26
KR20080004495A (ko) 2008-01-09
BRPI0608176A2 (pt) 2009-11-17
TW200722091A (en) 2007-06-16
US20060235006A1 (en) 2006-10-19
WO2006113304A3 (en) 2007-08-02
US20090054415A1 (en) 2009-02-26
MX2007012537A (es) 2007-12-10
JP2008536853A (ja) 2008-09-11
EP1868435A4 (en) 2009-04-01
AU2006236812A1 (en) 2006-10-26
EP1868435A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
NO20075154L (no) Formuleringer av en src/abl-inhibitor
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
DE60314013D1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
UA85686C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
SI1776349T1 (sl) 2-amino-kinazolinski derivati, uporabni kot zaviralci beta-sekretaze (bace)
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20073571L (no) Nye hydantoinderivater som metallproteinaseinhibitorer
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
TW200738714A (en) New secondary amines
ATE423105T1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
SE0402284D0 (sv) New heterocyclic amides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application